Article and Video CATEGORIES

Cancer Journey

Search By

Do You Order PD-L1 Testing Before Choosing an Immune Checkpoint Inhibitor?
Author
GRACE Videos and Articles

WCLC_2015_Order_PD-L1_Testing_Before_Choosing_Immune_Checkpoint_Inhibitor

 

Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.

[powerpress]

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

Dr. West:  One of the key differences that we’re seeing, is really, the strategy that the different companies take in terms of just different denominators, patient populations, and that some are, like nivolumab, is being largely tested in unselected populations looking at PD-L1 levels, or not looking at PD-L1 levels, while several of the other agents in this space are really being restricted to patients who are PD-L1 positive, and seem to, in most of the trials, have a better probability of long response. Do you see PD-L1, now, as an important biomarker that you would use if it’s not mandated — for instance, say, in the nivolumab patients with non-squamous disease?

Dr. Horn:  So, nivolumab, for first line, they are looking at PD-L1. So, when we’re talking about second or third line, with the squamous data, you know, I think a big part of the issue is, is tissue even available for testing? And if there is, which cut point do you use? We’ve even watched with atezolizumab, that cut points changed from their original phase one data, it was 5-10% and now we’re up to 50% cut point. So, right now the data suggests that you can use nivolumab regardless of PD-L1 status, it’s approved regardless of PD-L1 status, and so, that’s the way we’re doing it now. Our hospital is in the process of setting up PD-L1 testing, but it’s not there yet, and, so, the question is, if you are going to use the drug, which assay are you going to send out for, because there are different assays, and which commercial company are you going to send it to — the PD-L1 is a bit of a mess, and it requires a lot of work for us to sort out what to do.

Dr. West:  So Ben, where do you think we are now, and where are we going to be in a few years with this?

Dr. Solomon:  Yes, so look, I think what’s clear is that PD-L1 does enrich for a group of patients that are more likely to benefit. But I think what’s equally clear is that, if a patient is PD-L1 negative, there’s still a chance that they can benefit from treatment with a PD-1 or a PD-L1 inhibitor. So, this strategy of using PD-L1 to enrich for a group of patients who might want to, for example, use a PD-1 axis inhibitor for the first line, probably does make sense, but it probably doesn’t make sense to exclude a patient based on PD-L1 negativity, and the issues that Leora raised about which antibody to use, what lab to get the tests done in, what the cutoff is, absolutely — those are completely unresolved, and who is to know whether a PD-L1 result that you get from a private laboratory has any sort of relationship to the very rigorous, robust PD-L1 testing that’s done in the clinical trials.

Next Previous link

Previous PostNext Post

Related Content

Image
Blood Cancer OncTalk
Article
In this series of videos, Dr. Aaron Goodman chairs the discussion along with speakers Drs. Tycel Phillips, Sridvi Rajeeve, Marco Ruiz and Alankrita Taneja.  Topics include:
Article
View the full Targeted Therapies in Lung Cancer Patient forum from 2023 in YouTube and embedded here! 
Image
Terapias Dirigidas de Cáncer de Pulmón 2023
Video
En este foro anual de pacientes en vivo, los principales oncólogos torácicos de todo el mundo discuten temas relevantes para los objetivos del cáncer de pulmón, así como mutaciones raras. En esta serie de videos el Dr. Luis Corrales presenta una breve descripción de KRAS y explica los subtipos de NSCLC y sus opciones de tratamiento. Click aquí para ver la playlist completa.    

Forum Discussions

Hi Oaktowngrrl,  Welcome to Grace.  I'm so sorry you're going through this.

 

 Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...

Hello Hello,  Just want to let you know I see your post and will respond more appropriately in the morning. 

Hi, I'm sorry for the delay.  It's OK to post with questions here, it's what the forums are for.  However, our expertise is not in diagnosing cancer but in knowledge of...

Recent Comments

JOIN THE CONVERSATION
Hi Oaktowngrrl,  Welcome to…
By JanineT GRACE … on
I can understand why you're…
By paulryan on
I'm so sorry to hear it.
By Andrian on
Hey,

 I'm sure you're…
By JanineT GRACE … on